1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies
insider
insider
Articles 

Sofinnova Ventures Inc Buys NextCure Inc, PTC Therapeutics Inc, Acceleron Pharma Inc, Sells AstraZeneca PLC, Coherus BioSciences Inc, Alnylam Pharmaceuticals Inc

Investment company Sofinnova Ventures Inc (Current Portfolio) buys NextCure Inc, PTC Therapeutics Inc, Acceleron Pharma Inc, Vertex Pharmaceuticals Inc, Bristol-Myers Squibb Company, sells AstraZeneca PLC, Coherus BioSciences Inc, Alnylam Pharmaceuticals Inc, AnaptysBio Inc, Xencor Inc during the 3-months ended 2019Q2, according to the most recent filings of the investment company, Sofinnova Ventures Inc. As of 2019Q2, Sofinnova Ventures Inc owns 58 stocks with a total value of $986 million. These are the details of the buys and sells.

For the details of Sofinnova Ventures Inc's stock buys and sells, go to https://www.gurufocus.com/guru/sofinnova+ventures+inc/current-portfolio/portfolioportfolio

These are the top 5 holdings of Sofinnova Ventures Inc
  1. Ascendis Pharma A/S (ASND) - 1,099,824 shares, 12.85% of the total portfolio. Shares added by 10.14%
  2. Amarin Corp PLC (AMRN) - 5,208,305 shares, 10.24% of the total portfolio.
  3. Natera Inc (NTRA) - 3,100,560 shares, 8.67% of the total portfolio.
  4. Principia Biopharma Inc (PRNB) - 2,038,208 shares, 6.86% of the total portfolio.
  5. ObsEva SA (OBSV) - 4,749,623 shares, 5.45% of the total portfolio.
New Purchase: NextCure Inc (NXTC)

Sofinnova Ventures Inc initiated holding in NextCure Inc. The purchase prices were between $14.16 and $20.64, with an estimated average price of $17.39. The stock is now traded at around $26.71. The impact to a portfolio due to this purchase was 3.83%. The holding were 2,521,856 shares as of .

New Purchase: PTC Therapeutics Inc (PTCT)

Sofinnova Ventures Inc initiated holding in PTC Therapeutics Inc. The purchase prices were between $35.42 and $45, with an estimated average price of $39.44. The stock is now traded at around $46.40. The impact to a portfolio due to this purchase was 1.68%. The holding were 368,903 shares as of .

New Purchase: Acceleron Pharma Inc (XLRN)

Sofinnova Ventures Inc initiated holding in Acceleron Pharma Inc. The purchase prices were between $37.52 and $46.93, with an estimated average price of $41.39. The stock is now traded at around $45.99. The impact to a portfolio due to this purchase was 1%. The holding were 241,043 shares as of .

New Purchase: Vertex Pharmaceuticals Inc (VRTX)

Sofinnova Ventures Inc initiated holding in Vertex Pharmaceuticals Inc. The purchase prices were between $164.61 and $190.37, with an estimated average price of $174.67. The stock is now traded at around $183.91. The impact to a portfolio due to this purchase was 0.94%. The holding were 50,301 shares as of .

New Purchase: Bristol-Myers Squibb Company (BMY)

Sofinnova Ventures Inc initiated holding in Bristol-Myers Squibb Company. The purchase prices were between $44.62 and $49.34, with an estimated average price of $46.57. The stock is now traded at around $46.49. The impact to a portfolio due to this purchase was 0.8%. The holding were 173,849 shares as of .

New Purchase: ACADIA Pharmaceuticals Inc (ACAD)

Sofinnova Ventures Inc initiated holding in ACADIA Pharmaceuticals Inc. The purchase prices were between $23.32 and $28.12, with an estimated average price of $25.52. The stock is now traded at around $29.45. The impact to a portfolio due to this purchase was 0.42%. The holding were 155,576 shares as of .

Added: TG Therapeutics Inc (TGTX)

Sofinnova Ventures Inc added to a holding in TG Therapeutics Inc by 258.54%. The purchase prices were between $6.27 and $8.65, with an estimated average price of $7.56. The stock is now traded at around $7.19. The impact to a portfolio due to this purchase was 0.8%. The holding were 1,261,384 shares as of .

Added: Heron Therapeutics Inc (HRTX)

Sofinnova Ventures Inc added to a holding in Heron Therapeutics Inc by 164.15%. The purchase prices were between $16.93 and $26.22, with an estimated average price of $20. The stock is now traded at around $18.17. The impact to a portfolio due to this purchase was 0.72%. The holding were 617,185 shares as of .

Added: Biomarin Pharmaceutical Inc (BMRN)

Sofinnova Ventures Inc added to a holding in Biomarin Pharmaceutical Inc by 359.05%. The purchase prices were between $80.35 and $93.9, with an estimated average price of $85.56. The stock is now traded at around $73.46. The impact to a portfolio due to this purchase was 0.58%. The holding were 84,896 shares as of .

Added: Halozyme Therapeutics Inc (HALO)

Sofinnova Ventures Inc added to a holding in Halozyme Therapeutics Inc by 71.98%. The purchase prices were between $14.75 and $17.26, with an estimated average price of $16.12. The stock is now traded at around $16.22. The impact to a portfolio due to this purchase was 0.5%. The holding were 690,199 shares as of .

Added: Reata Pharmaceuticals Inc (RETA)

Sofinnova Ventures Inc added to a holding in Reata Pharmaceuticals Inc by 77.66%. The purchase prices were between $77.72 and $94.35, with an estimated average price of $86.24. The stock is now traded at around $77.71. The impact to a portfolio due to this purchase was 0.49%. The holding were 115,536 shares as of .

Added: Novo Nordisk A/S (NVO)

Sofinnova Ventures Inc added to a holding in Novo Nordisk A/S by 30.66%. The purchase prices were between $46.79 and $52.47, with an estimated average price of $49.39. The stock is now traded at around $51.85. The impact to a portfolio due to this purchase was 0.39%. The holding were 323,697 shares as of .

Sold Out: AstraZeneca PLC (AZN)

Sofinnova Ventures Inc sold out a holding in AstraZeneca PLC. The sale prices were between $37.28 and $41.68, with an estimated average price of $39.2.

Sold Out: AnaptysBio Inc (ANAB)

Sofinnova Ventures Inc sold out a holding in AnaptysBio Inc. The sale prices were between $53.76 and $81.12, with an estimated average price of $72.07.

Sold Out: Xencor Inc (XNCR)

Sofinnova Ventures Inc sold out a holding in Xencor Inc. The sale prices were between $29.6 and $40.93, with an estimated average price of $32.83.

Sold Out: Biohaven Pharmaceutical Holding Co Ltd (BHVN)

Sofinnova Ventures Inc sold out a holding in Biohaven Pharmaceutical Holding Co Ltd. The sale prices were between $39.79 and $67.01, with an estimated average price of $56.51.

Sold Out: Blueprint Medicines Corp (BPMC)

Sofinnova Ventures Inc sold out a holding in Blueprint Medicines Corp. The sale prices were between $73.54 and $97.8, with an estimated average price of $82.43.

Sold Out: Savara Inc (SVRA)

Sofinnova Ventures Inc sold out a holding in Savara Inc. The sale prices were between $2.37 and $11.7, with an estimated average price of $8.93.



Here is the complete portfolio of Sofinnova Ventures Inc. Also check out:

1. Sofinnova Ventures Inc's Undervalued Stocks
2. Sofinnova Ventures Inc's Top Growth Companies, and
3. Sofinnova Ventures Inc's High Yield stocks
4. Stocks that Sofinnova Ventures Inc keeps buying

Rating: 0.0/5 (0 votes)

Comments

Please leave your comment:


Performances of the stocks mentioned by insider


User Generated Screeners


pjmason14Momentum
pascal.van.garsseHigh FCF-M2
kosalmmuse6
kosalmmuseBest one1
DBrizanall 2019Feb26
kosalmmuseBest one
DBrizanall 2019Feb25
kosalmmuseNice
kosalmmusehan
MsDale*52-Week Low
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}
FEEDBACK